Navigation Links
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
Date:1/13/2009

-Growing Body of Data Supports XELOX as Effective Alternative to Standard of Care-

NUTLEY, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Overall survival results from a 14-month follow-up of the international, Phase III NO16966 study confirm that oral Xeloda(R) plus oxaliplatin (XELOX) is comparable to a current standard treatment, FOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin) in the first-line treatment of advanced (metastatic) colorectal cancer.

In the study, patients receiving XELOX lived for a median of 19.0 months, while patients receiving FOLFOX-4 lived for a median of 18.5 months. The consistency of these results were also further demonstrated in a subset population from the original two-arm part of the study (XELOX v. FOLFOX). These data will be presented later this week at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, Calif.

"These compelling data validate previous studies showing that XELOX is comparable to FOLFOX-4 for the treatment of advanced colorectal cancer, while providing the added flexibility of the proven oral component Xeloda," said Edward Chu, M.D., chief of medical oncology, Yale Cancer Center. "Together, these studies confirm the value and importance of combination therapy with oral Xeloda for the thousands of patients with this insidious disease."

Colorectal cancer is the third most common cancer in the United States. The American Cancer Society estimated that in 2008 more than 148,000 people in the U.S. would be diagnosed and about 50,000 people would die from the disease. (1)

Previous data reported from the NO16966 study showed that XELOX is comparable to FOLFOX-4 in terms of progression-free survival, and the addition of Avastin to chemotherapy (FOLFOX-4 and XELOX) significantly improved progression-free survival by investigator assessment compared to chemotherapy alone. Fu
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
2. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
3. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
4. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
5. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
6. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
7. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
8. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
9. New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
10. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
11. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2009)...eeks to Assess RSV Burden in Outpatient Setting Du... Pediatric Research , , GAITHERSBURG, Md., Ju...ce its commitment to pediatric research with today...tive study designed to assess the burden of respir...32-to-35 weeks gestational age (GA) in outpatient ...
(Date:6/29/2009)... for Novel Biotherapeutics Based On Naturally Rese...PRNewswire/ -- Pangu BioPharma, a subsidiary of aT... of its third patent application on proprietary, n...s. Although tRNA synthetases are universal and es...found in all organisms, human synthetases have nat...
(Date:6/28/2009)...RONADO, Portugal, June 29 Data pre...on treatment with the novel,once-daily anti-epil...esulted,in a marked and sustained decrease in sei...ults from the one-year extension of a pivotal Esli...d at the International Congress for Epilepsy in,B...
(Date:6/26/2009)...June 26 Sanofi-aventis...de aware of data associated with a retrospective f...f these data clearly show that no definitive concl...lationship between Lantus(R) (insulin glargine [rD...ies, as the authors of the study point out. , ,...
Breaking Medicine Technology:MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 2Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 4Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 5Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 6Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 7Sanofi-aventis Stands Behind the Safety of Lantus(R) 2Sanofi-aventis Stands Behind the Safety of Lantus(R) 3Thursday May 22 is Health Care Action Day 19934 1Thursday May 22 is Health Care Action Day 19934 2LPGA Competitors and Friends Come Together for Breast Cancer 19932 1LPGA Competitors and Friends Come Together for Breast Cancer 19932 2Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies 2143 1Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies 2143 2Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies 2143 3Oxidized LDL Cholesterol Linked to Metabolic Syndrome 19929 1Oxidized LDL Cholesterol Linked to Metabolic Syndrome 19929 2Oxidized LDL Cholesterol Linked to Metabolic Syndrome 19929 3
...abled more and more laboratory testing to occur at...oratory is hardly threatened with extinction. Nati...s are busier than ever before, and the huge range ...nd ability to handle very large volumes of tests a... clinical landscape. , ,This is especially tru...
...n this country cause more than 114,000 hospitaliza...ults, bronchitis and pneumonia are the most common...are the sixth leading cause of death in the United...derly and immunocompromised people; however, infec...rious illnesses in any patient. Prompt diagnosis o...
Other Medicine Technology:When Volume Matters, Immunoassay Systems Deliver 2When Volume Matters, Immunoassay Systems Deliver 3Fast, Accurate Influenza A/B Antigen Detection 2Fast, Accurate Influenza A/B Antigen Detection 3
(Date:7/3/2009)...n Whitaker, MD, a founder of the alternative healt...tpain.com, a new informational Web site devoted to...lutions. , Potomac, MD (V...er of the alternative health movement, is now a fe...ational Web site devoted to all aspects of joint a...
(Date:7/3/2009)...e health care reform details emerge, more entrepre...ll groups and business insurance premiums. Now, th...sites such as the Small Business Health Insurance ... Minneapolis, Minn. (PRWEB) July 3, 2009 -- The...he House, which has entrepreneurs worried about ho...
(Date:7/2/2009)...rs to Support Principles to Govern Health Insurer ...wire-USNewswire/ -- Nearly nine out of ten voters ... too much influence over how doctors care for thei...rt the concept of a "Health Insurer Code of Conduc...es for health insurance companies with respect to ...
(Date:7/2/2009)...RNewswire-USNewswire/ -- Acetaminophen is an ingre...ion medicines to help relieve pain and reduce feve...name, Tylenol and prescription brand names, Vicodi...the FDA met on June 30, 2009 to address liver rela... committee voted 20-17 to urge the FDA to put a ba...
Breaking Medicine News(10 mins):Health News:Dr. Julian Whitaker Featured on Searchjointpain.com 2Health News:Health Care Reform Details Emerge with 'Play or Pay' Requirements, Leaving Some Wondering about Small Business Owner Insurance 2Health News:Health Care Reform Details Emerge with 'Play or Pay' Requirements, Leaving Some Wondering about Small Business Owner Insurance 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 2Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 4Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 5Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 6Health News:Viles & Beckman, LLC: Stop Your Headache NOT Your Liver 2
..., a bacterium commonly found in hospitals, is beco...reat,// reports the April 2007 issue of Harvard Wo...t a new, more virulent strain may be to blame. Ce...oxins that attack the cells lining the colon. Thos...
...ry patients are more likely to suffer infections a...ng to cardiothoracic surgeons in Victoria. Dr Che...m St Vincent's hospital inMelbourne, and colleague...rtery bypass grafting or heart valvesurgery are 1....
... to predict whether a person is likely to have cor...h carried out by Dr. M. Balasubramanyam and Dr.V.M...ndia) shows that people who are pre-diabetic or wh...s1 and, since these people are prone to CAD, an ea...
...kal’ that is aimed for the diabetics, obese and th... India Pharma - USV Ltd//. Cutkal has a combinatio...is the same that is used in diet colas around the ...1981 and is used in 6,000 products like beverages,...
Other Medicine News:Health News:Obese Heart Patients At Greater Risk 2Health News:New Genetic Biomarkers Could Predict Coronary Heart Disease 2
The Wide-Vu magnifier is our most popular Low Vision telescope for reading. It offers a wide field of view than the LVA21 and hence a slightly shorter working distance. The Wide-Vu can be mounted to
The Redi-glaze spectacle magnifier is an aspheric lens, glazed into a standard Keeler LVA frame.
This set is designed to introduce the low vision practitioner to the Keeler telescopic system.
Featuring up to 20 tilting tower illumination allows examination in the vertical, horizontal and oblique sections plus the option to offset the slit for corneal transillumination., ,Filters inclu
Medicine Products: